[go: up one dir, main page]

AR046811A1 - Formas de dosificacion oral de ziprasidona de liberacion sostenida - Google Patents

Formas de dosificacion oral de ziprasidona de liberacion sostenida

Info

Publication number
AR046811A1
AR046811A1 ARP040103123A ARP040103123A AR046811A1 AR 046811 A1 AR046811 A1 AR 046811A1 AR P040103123 A ARP040103123 A AR P040103123A AR P040103123 A ARP040103123 A AR P040103123A AR 046811 A1 AR046811 A1 AR 046811A1
Authority
AR
Argentina
Prior art keywords
ziprasidone
oral dosage
sustained release
stable state
dosage forms
Prior art date
Application number
ARP040103123A
Other languages
English (en)
Inventor
Imran Ahmed
Walter Christian Babcock
Scott Max Herbig
Sheri L Shamblin
Daniel Tod Smithey
Avinash Govind Thombre
Dwayne Thomas Friesen
David Keith Lyon
Ravi Mysore Shanker
Steven C Sutton
Kenneth C Waterman
Leah Elizabeth Appel
Original Assignee
Imran Ahmed
Scott Max Herbig
Dwayne Thomas Friesen
Walter Christian Babcock
David Keith Lyon
Steven C Sutton
Sheri L Shamblin
Avinash Govind Thombre
Ravi Mysore Shanker
Leah Elizabeth Appel
Daniel Tod Smithey
Kenneth C Waterman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imran Ahmed, Scott Max Herbig, Dwayne Thomas Friesen, Walter Christian Babcock, David Keith Lyon, Steven C Sutton, Sheri L Shamblin, Avinash Govind Thombre, Ravi Mysore Shanker, Leah Elizabeth Appel, Daniel Tod Smithey, Kenneth C Waterman filed Critical Imran Ahmed
Publication of AR046811A1 publication Critical patent/AR046811A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Forma de dosificación oral sólida de ziprasidona de liberación sostenida para el tratamiento de un trastorno psicótico, por ejemplo, esquizofrenia, en un mamífero. Reivindicación 1: Un forma de dosificación oral de liberación sostenida que comprende una cantidad farmacéuticamente efectiva de ziprasidona y un medio de liberación sostenida para liberar por lo menos una parte de dicha ziprasidona, en donde después de la administración para alcanzar un estado estable, dicha forma de dosificación proporciona una concentración de ziprasidona en sangre mínima (Cmin) en estado estable de por lo menos 20 ng/ml y una concentración de ziprasidona en sangre máxima (Cmax) en estado estable de menos de 330 ng/ml.
ARP040103123A 2003-09-02 2004-08-31 Formas de dosificacion oral de ziprasidona de liberacion sostenida AR046811A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49948403P 2003-09-02 2003-09-02

Publications (1)

Publication Number Publication Date
AR046811A1 true AR046811A1 (es) 2005-12-28

Family

ID=34272825

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103123A AR046811A1 (es) 2003-09-02 2004-08-31 Formas de dosificacion oral de ziprasidona de liberacion sostenida

Country Status (16)

Country Link
US (2) US20070190129A1 (es)
EP (1) EP1663166A2 (es)
JP (1) JP2007504266A (es)
KR (3) KR20080093464A (es)
CN (1) CN1874761A (es)
AR (1) AR046811A1 (es)
AU (1) AU2004268663B2 (es)
BR (1) BRPI0414082A (es)
CA (1) CA2537413A1 (es)
IL (1) IL173866A0 (es)
MX (1) MXPA06002455A (es)
NO (1) NO20061517L (es)
RU (1) RU2351316C2 (es)
TW (1) TW200526221A (es)
WO (1) WO2005020929A2 (es)
ZA (1) ZA200601602B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
JP4806507B2 (ja) 1999-10-29 2011-11-02 ユーロ−セルティーク エス．エイ． 制御放出ヒドロコドン処方
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
JP5547865B2 (ja) 2003-10-29 2014-07-16 ワイス・エルエルシー アプリンドルおよびその誘導体を含む持続放出型医薬組成物
US8207232B2 (en) 2004-05-28 2012-06-26 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
BRPI0514416A (pt) * 2004-08-31 2008-06-10 Pfizer Prod Inc formas de dosagem de liberação controlada combinando liberação imediata e liberação controlada de um fármaco de baixa solubilidade
CN101123951A (zh) 2004-08-31 2008-02-13 辉瑞产品公司 包括低溶解性药物和聚合物的药物剂型
CA2603189A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
CA2605153A1 (en) * 2005-04-13 2006-10-19 Jaymin Chandrakant Shah Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
MX2007016151A (es) * 2005-06-20 2008-03-06 Elan Pharma Int Ltd Composiciones de liberacion controlada y en forma de nano-particulas que comprenden compuestos aril-heterociclicos.
HK1117060A1 (en) * 2005-06-20 2009-01-09 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
US8747897B2 (en) * 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
GB2446166B (en) * 2007-01-29 2010-05-12 Teraview Ltd A pharmaceutical analysis method and apparatus
MX2009011681A (es) * 2007-05-18 2009-11-10 Scidose Llc Formulaciones de ziprasidona.
EP2240162A4 (en) 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
EP2231169B1 (en) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
MX2010009844A (es) * 2008-03-07 2010-09-30 Pfizer Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento.
SA109300195B1 (ar) * 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
DE102008045854A1 (de) * 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
CN102988318A (zh) * 2008-11-25 2013-03-27 田边三菱制药株式会社 口腔速崩片及其制备方法
RU2421230C2 (ru) * 2009-07-23 2011-06-20 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ предотвращения десульфатирования и повышения биодоступности биологически активных сульфатированных полисахаридов при их пероральном применении
CN102234272A (zh) * 2010-04-21 2011-11-09 上海医药工业研究院 盐酸齐拉西酮半水合物的制备方法
EP2564837B1 (en) * 2010-04-30 2019-01-30 Takeda Pharmaceutical Company Limited Enteric tablet
WO2011148253A2 (en) * 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
PL391810A1 (pl) * 2010-07-14 2012-01-16 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Nowe sole ziprasidonu oraz sposoby ich otrzymywania
EP2654939A2 (en) * 2010-12-21 2013-10-30 President and Fellows of Harvard College Spray drying techniques
AU2012225459A1 (en) * 2011-03-08 2013-10-10 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
UY34856A (es) * 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
JP6041823B2 (ja) * 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
MX377576B (es) * 2014-01-22 2025-03-04 Prilenia Neurotherapeutics Ltd Formulaciones de pridopidina de liberación modificada.
PT3107544T (pt) 2014-02-21 2021-01-05 Principia Biopharma Inc Sais e forma sólida de um inibidor de btk
CA2970723C (en) 2014-12-18 2023-09-05 Principia Biopharma Inc. Treatment of pemphigus
EA036351B1 (ru) * 2014-12-24 2020-10-29 Принсипиа Биофарма Инк. Твердая пероральная лекарственная форма для ингибирования btk и способы лечения
EP3313839A1 (en) 2015-06-24 2018-05-02 Principia Biopharma Inc. Tyrosine kinase inhibitors
JP6855469B2 (ja) * 2015-10-16 2021-04-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 消化器標的療法のための処方物を調製するための工程
IL293621B2 (en) 2016-06-29 2023-09-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile
BR112019010785A8 (pt) * 2016-11-28 2022-08-09 Currahee Holding Company Inc Processo para produzir uma forma de dosagem revestida
AU2019228497B2 (en) * 2018-02-27 2025-01-16 Delpor, Inc. Compositions for small molecule therapeutic agent compounds
CN109725092A (zh) * 2019-03-19 2019-05-07 北京和合医学诊断技术股份有限公司 检测血液中齐拉西酮含量的液相色谱分析方法
CA3154257A1 (en) 2019-10-14 2021-04-22 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
AU2021209884A1 (en) 2020-01-22 2022-09-15 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
EP4247340A4 (en) * 2020-11-18 2024-10-02 Bexson Biomedical, Inc. COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2261678A (en) * 1937-06-17 1941-11-04 Westinghouse Electric & Mfg Co Electrical flasher system
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
ES2163504T5 (es) * 1994-05-06 2008-05-16 Pfizer Inc. Formas de dosificacion de liberacion controlada de azitromicina.
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JP3102896B2 (ja) * 1996-05-07 2000-10-23 ファイザー インク． ５―（２―（４―（１，２―ベンズイソチアゾール―３―イル）―１―ピペラジニル）エチル）―６―クロロ―１，３―ジヒドロ―２（１ｈ）―インドール―２―オン（＝ジプラシドン）のメシレート三水和物、その調製法およびドーパミンｄ２アンタゴニストとしてのその使用
GB9706714D0 (en) * 1997-04-02 1997-05-21 Reckitt & Colman Inc Improvements in or relating to organic compositions
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
ATE400251T1 (de) * 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US7030142B1 (en) * 1999-04-06 2006-04-18 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using ziprasidone metabolites
JP4100910B2 (ja) * 1999-12-23 2008-06-11 ファイザー・プロダクツ・インク ヒドロゲル駆動の薬物剤形
DZ3227A1 (fr) * 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6753011B2 (en) * 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
MXPA05002561A (es) * 2002-10-25 2005-05-05 Pfizer Prod Inc Nuevas formulaciones de liberacion prolongada inyectables.
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
TW200500067A (en) * 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
JP2006528676A (ja) * 2003-05-16 2006-12-21 ファイザー・プロダクツ・インク 非定形型抗精神病薬と、ｇａｂａ調節薬及び／又は抗痙攣薬の治療上の組合せ
US20050038047A1 (en) * 2003-08-14 2005-02-17 Edwards Paul John Azaquinazoline derivatives
WO2005065660A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Ziprasidone formulations
CA2605153A1 (en) * 2005-04-13 2006-10-19 Jaymin Chandrakant Shah Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions

Also Published As

Publication number Publication date
KR20060115350A (ko) 2006-11-08
NO20061517L (no) 2006-06-02
AU2004268663B2 (en) 2010-12-09
US20070190129A1 (en) 2007-08-16
RU2006106464A (ru) 2007-09-10
EP1663166A2 (en) 2006-06-07
KR20080093464A (ko) 2008-10-21
CN1874761A (zh) 2006-12-06
MXPA06002455A (es) 2006-08-31
CA2537413A1 (en) 2005-03-10
BRPI0414082A (pt) 2006-10-24
AU2004268663A1 (en) 2005-03-10
KR20090080143A (ko) 2009-07-23
WO2005020929A2 (en) 2005-03-10
TW200526221A (en) 2005-08-16
US20100003331A1 (en) 2010-01-07
WO2005020929A3 (en) 2005-08-25
ZA200601602B (en) 2007-05-30
JP2007504266A (ja) 2007-03-01
IL173866A0 (en) 2006-07-05
RU2351316C2 (ru) 2009-04-10

Similar Documents

Publication Publication Date Title
AR046811A1 (es) Formas de dosificacion oral de ziprasidona de liberacion sostenida
UY27532A1 (es) Forma de dosificación de liberación controlada dual.
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
FR2878159B1 (fr) Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
AR027091A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
CL2008002407A1 (es) Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04).
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
AR040722A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
PE109599A1 (es) Formas de dosificacion farmaceuticas solidas
DE602005011105D1 (de) Implantierbare arzneiabgabevorrichtung mit drahtfäden
ITMI20001173A0 (it) Composizioni farmaceutiche a rilascio prolungato per la somministrazione parenterale di sostanze idrofile biologicamente attiva.
DOP2001000229A (es) Forma de dosificación de fármaco activada por hidrogel
CL2008000750A1 (es) Metodo para la administracion de una dosis semanal de 2-[6-(3-amino-piperidin-1-il)3-metil-2,4 dioxo-3,4 dihidro-2h-pirimidin-1-il metil]-4 fluoro-benzonitrilo; composicion farmaceutica de una forma de dosificacion individual de dicho compuesto; y su
SV2002000969A (es) Composicion parenteral reconstituible
CO5540373A2 (es) Composicion farmaceutica de liberacion sostenida
AR034517A1 (es) Formulacion farmaceutica
AR052052A1 (es) Terapia de combinacion
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
AR032642A1 (es) Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponibilidad oral.
CL2007003010A1 (es) Forma de dosificacion oral que comprende un nucleo erosionable que contiene un principio activo de caracter basico debil, un recubrimiento erosionable en torno a dicho nucleo con una o mas abertura que atraviesn el recubrimiento y conectan al nucleo con el medio de uso; procedimiento de preparacion; y uso (divisional de 260-03).
CR7049A (es) Empleo de flumazenilo en la elaboracion de una medicacion para el tratamiento de la dependencia del alcohol
WO2006023644A3 (en) Transdermal drug delivery device with translucent protective film
ATE552826T1 (de) Pharmazeutische formulierungen mit clopidogrel

Legal Events

Date Code Title Description
FB Suspension of granting procedure